Literature DB >> 2207003

Haemophilia protects against ischaemic heart disease: a study of risk factors.

F R Rosendaal1, E Briët, J Stibbe, G van Herpen, J A Leuven, A Hofman, J P Vandenbroucke.   

Abstract

We previously reported that mortality due to ischaemic heart disease was lower in haemophilia patients than in the general male population. To support the hypothesis that this could be attributed to a protective effect of the clotting defect in haemophilia and not to differences in cardiovascular risk factors, we performed a second study. We examined 95 haemophilia patients for the presence of major risk factors for ischaemic heart disease and compared their risk factor profile with the data of epidemiologic surveys of the general Dutch population. Haemophilia patients had on average higher blood pressures than the comparison population, were more often hypertensive and used antihypertensive drugs twice as often. The mean serum cholesterol level of the patients was markedly lower than in the comparison population (4.8 versus 5.6 mmol/l, 95% confidence interval of the difference: 0.5-1.1 mmol/l). The risk factors were weighted into one theoretical risk ratio for ischaemic heart disease by application of logistic regression coefficients. The theoretical risk ratio based on the risk factor profile was 0.78. This risk ratio can only explain a moderate reduction in the incidence of ischaemic heart disease, much smaller than the mortality ratio of 0.20 we reported previously. Therefore these data support the hypothesis of a direct protective effect of haemophilia on the development of ischaemic heart disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2207003     DOI: 10.1111/j.1365-2141.1990.tb07793.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  20 in total

Review 1.  Factoring in Factor VIII With Acute Ischemic Stroke.

Authors:  James E Siegler; Alyana Samai; Karen C Albright; Amelia K Boehme; Sheryl Martin-Schild
Journal:  Clin Appl Thromb Hemost       Date:  2015-02-10       Impact factor: 2.389

Review 2.  Arterial and venous thrombosis in patients with von Willebrand's disease: a critical review of the literature.

Authors:  A Girolami; F Tezza; M Scapin; S Vettore; A Casonato
Journal:  J Thromb Thrombolysis       Date:  2006-04       Impact factor: 2.300

Review 3.  Hemophilia treatment in historical perspective: a review of medical and social developments.

Authors:  F R Rosendaal; C Smit; E Briët
Journal:  Ann Hematol       Date:  1991-02       Impact factor: 3.673

4.  Coronary atherosclerosis and cardiovascular mortality in hemophilia.

Authors:  C J Foley; L Nichols; K Jeong; C G Moore; M V Ragni
Journal:  J Thromb Haemost       Date:  2009-10-26       Impact factor: 5.824

5.  Atherosclerotic heart disease: prevalence and risk factors in hospitalized men with haemophilia A.

Authors:  M V Ragni; C G Moore
Journal:  Haemophilia       Date:  2011-03-04       Impact factor: 4.287

Review 6.  Non-catheter associated venous thrombosis in hemophilia A and B. A critical review of all reported cases.

Authors:  Antonio Girolami; Raffaella Scandellari; Ezio Zanon; Roberto Sartori; Bruno Girolami
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

Review 7.  Myocardial infarction, other arterial thrombosis and invasive coronary procedures, in hemaophilia B: a critical evaluation of reported cases.

Authors:  A Girolami; M L Randi; E Ruzzon; E Zanon; B Girolami
Journal:  J Thromb Thrombolysis       Date:  2005-08       Impact factor: 2.300

8.  Acute kidney injury in a diabetic haemophiliac: one step at a time.

Authors:  Mohammed Mahdi Althaf; Maged Hassan Hussein; Mohamed Said Abdelsalam; Sadiq Mohammed Amer
Journal:  BMJ Case Rep       Date:  2014-05-08

9.  Factor VIII and coronary heart disease.

Authors:  F R Rosendaal
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

10.  Coronary artery bypass surgery, angioplasty and long term anti-platelet treatment in a type B hemophilia patient.

Authors:  Antonio Eduardo Pesaro; Marcus Vinicius Gaz; Ralf Karbstein; Marco Perin; Carlos Vicente Serrano; Elbio Damico
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.